• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    2/14/23 9:45:01 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    SC 13G/A 1 d461502dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    LENSAR, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    52634L108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 52634L108    13G   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Silver Point Capital, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      -0-

       6  

      SHARED VOTING POWER

     

      480,845

       7  

      SOLE DISPOSITIVE POWER

     

      -0-

       8  

      SHARED DISPOSITIVE POWER

     

      480,845

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      480,845

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.4%1

    12  

      TYPE OF REPORTING PERSON*

     

      IA, PN

     

    1

    The percentages used herein and in the rest of this Amendment No. 2 to Schedule 13G are calculated based upon 11,023,304 shares of the Issuer’s common stock outstanding as of October 31, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2022.

     

    2 of 10


    CUSIP NO. 52634L108    13G   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Edward A. Mulé

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      -0-

       6  

      SHARED VOTING POWER

     

      480,845

       7  

      SOLE DISPOSITIVE POWER

     

      -0-

       8  

      SHARED DISPOSITIVE POWER

     

      480,845

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      480,845

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.4%1

    12  

      TYPE OF REPORTING PERSON*

     

      IN

     

    3 of 10


    CUSIP NO. 52634L108    13G   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Robert J. O’Shea

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      -0-

       6  

      SHARED VOTING POWER

     

      480,845

       7  

      SOLE DISPOSITIVE POWER

     

      -0-

       8  

      SHARED DISPOSITIVE POWER

     

      480,845

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      480,845

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.4%1

    12  

      TYPE OF REPORTING PERSON*

     

      IN

     

    4 of 10


    Item 1 (a)    Name of Issuer:
       The name of the issuer is LENSAR, Inc. (the “Company”), a Delaware corporation.
    (b)    Address of Issuer’s Principal Executive Offices:
       The Company’s principal executive office is located at 2800 Discovery Drive, Orlando, Florida 32826.
    Item 2(a)    Name of Person Filing:
      

    This Amendment No. 2 to Schedule 13G (“Amendment No.2”) is being jointly filed by Silver Point Capital, L.P., a Delaware limited partnership (“Silver Point”), Mr. Edward A. Mulé and Mr. Robert J. O’Shea with respect to the ownership of the common stock of the Company by Silver Point Capital Fund, L.P. , Silver Point Capital Offshore Master Fund, L.P. , Silver Point Distressed Opportunities Fund, L.P., Silver Point Distressed Opportunities Offshore Master Fund, L.P., Silver Point Distressed Opportunity Institutional Partners, L.P. and Silver Point Distressed Opportunity Institutional Partners Master Fund (Offshore), L.P.2 Silver Point, Mr. Mulé and Mr. O’Shea are collectively referred to herein as the “Reporting Persons.”

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2023, a copy of which is filed with this Amendment No. 2 as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

    (b)    Address of Principal Business Office or, if none, Residence:
       The address of the principal business office of each of the Reporting Persons is Two Greenwich Plaza, Greenwich, CT 06830.
    (c)    Citizenship:
       Silver Point Capital, L.P. is organized as a limited partnership under the laws of the State of Delaware. Both Mr. Mulé and Mr. O’Shea are U.S. citizens.
    (d)    Title of Class of Securities:
       Common Stock, par value $0.01 per share
    (e)    CUSIP No.:
       52634L108
    Item 3    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:
       Not Applicable

     

    2

    The funds listed in Item 2(a) above (collectively, the “Funds”) are managed by Silver Point or its wholly owned subsidiaries. Silver Point Capital Management, LLC (“Management”) is the general partner of Silver Point and as a result may be deemed to be the beneficial owner of the securities held by the Funds. Each of Mr. Edward A. Mulé and Mr. Robert J. O’Shea is a member of Management and has voting and investment power with respect to the securities held by the Funds and may be deemed to be a beneficial owner of the securities held by the Funds.

     

    5 of 10


    Item 4 Ownership:

     

    A.    Silver Point Capital, L.P.
       (a) Amount beneficially owned: 480,845
       (b) Percent of class: 4.4%
       (c) Number of shares as to which such person has:
      

    (i) Sole power to vote or direct the vote: -0-

      

    (ii) Shared power to vote or direct the vote: 480,845

      

    (iii) Sole power to dispose or direct the disposition: -0-

      

    (iv) Shared power to dispose or direct the disposition: 480,845

    B.    Edward A. Mulé
       (a) Amount beneficially owned: 480,845
       (b) Percent of class: 4.4%
       (c) Number of shares as to which such person has:
      

    (i) Sole power to vote or direct the vote: -0-

      

    (ii) Shared power to vote or direct the vote: 480,845

      

    (iii) Sole power to dispose or direct the disposition: -0-

      

    (iv) Shared power to dispose or direct the disposition: 480,845

    C.    Robert J. O’Shea
       (a) Amount beneficially owned: 480,845
       (b) Percent of class: 4.4%
       (c) Number of shares as to which such person has:
      

    (i) Sole power to vote or direct the vote: -0-

      

    (ii) Shared power to vote or direct the vote: 480,845

      

    (iii) Sole power to dispose or direct the disposition: -0-

      

    (iv) Shared power to dispose or direct the disposition: 480,845

     

    6 of 10


    Item 5    Ownership of Five Percent or Less of a Class:
       If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
    Item 6    Ownership of More Than Five Percent on Behalf of Another Person:
       See response to Item 4.
    Item 7    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
       Not applicable.
    Item 8    Identification and Classification of Members of the Group:
       Not applicable.
    Item 9    Notice of Dissolution of Group:
       Not applicable.
    Item 10    Certification:
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    7 of 10


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 2 to Schedule 13G is true, complete and correct.

    Date: February 14, 2023

     

    Silver Point Capital, L.P.
    By:  

    /s/ Steven Weiser

    Name:   Steven Weiser
    Its:   Authorized Signatory
    Edward A. Mulé
    By:  

    /s/ Steven Weiser

    Name:   Steven Weiser
    Title:   Attorney-in-fact
    Robert J. O’Shea
    By:  

    /s/ Steven Weiser

    Name:   Steven Weiser
    Title:   Attorney-in-fact

     

    8 of 10


    EXHIBIT INDEX

     

    Exhibit

      

    Description of Exhibit

    Exhibit A    Joint Filing Agreement dated February 14, 2023.
    Exhibit B    Power of Attorney of Edward A. Mulé (incorporated here by reference to Exhibit B to Schedule 13G filed by Silver Point Capital, L.P., Edward A. Mulé and Robert O’Shea with the Securities and Exchange Commission on February 16, 2016 relating to TopBuild Corp.).
    Exhibit C    Power of Attorney of Robert O’Shea (incorporated here by reference to Exhibit C to Schedule 13G filed by Silver Point Capital, L.P., Edward A. Mulé and Robert O’Shea with the Securities and Exchange Commission on February 16, 2016 relating to TopBuild Corp.).

     

    9 of 10

    Get the next $LNSR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      9/6/24 9:00:13 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      8/29/24 6:05:46 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      8/23/24 6:52:16 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the new empl

      7/1/25 4:01:11 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted 10 newly-hired non-executive employees an aggregate of 3,090 restricted stock units ("RSUs"). The RSUs were granted as of June 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the new emplo

      6/2/25 4:01:08 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR Reports First Quarter 2025 Results and Provides Business Update

               14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

      5/8/25 7:00:42 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG initiated coverage on LENSAR with a new price target

      BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

      11/22/21 6:09:40 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SVB Leerink initiated coverage on LENSAR with a new price target

      SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

      3/2/21 8:10:50 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SVB Leerink initiated coverage on LENSAR with a new price target

      SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

      2/24/21 6:12:20 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    SEC Filings

    See more
    • LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - LENSAR, Inc. (0001320350) (Filer)

      7/2/25 4:00:35 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by LENSAR Inc.

      DEFA14A - LENSAR, Inc. (0001320350) (Filer)

      6/25/25 5:00:35 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by LENSAR Inc.

      DEFA14A - LENSAR, Inc. (0001320350) (Filer)

      5/22/25 4:47:59 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ellis Thomas B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:57:30 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Hammer Todd B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:56:24 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M was granted 7,374 shares, increasing direct ownership by 9% to 88,214 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:30:14 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      11/14/24 4:05:15 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      2/14/24 4:05:39 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      2/13/24 4:30:02 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Financials

    Live finance-specific insights

    See more
    • LENSAR Reports First Quarter 2025 Results and Provides Business Update

               14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

      5/8/25 7:00:42 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

      2/27/25 7:00:11 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025

      ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance

      2/19/25 12:00:25 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care